AC Immune Gets Another Payment After Advancing Phase 2b ReTain Trial for ACI-35.030 in Early Alzheimer’s.

This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.

the FDA approved several new drugs and new indications, including Roche's two blockbuster subcutaneous formulations, Eli Lilly's IL-13 antibody, and Johnson & Johnson's IL-23 antibody.

NextCure has disclosed that clinical findings from the Phase 1b segment of a Phase 1b/2 trial assessing NC410, a LAIR-2 fusion protein.

Trishula Therapeutics Shows Promising Phase 1 Results for TTX-030 in Initial Treatment of Metastatic Pancreatic Cancer.

ImmVira Presents Clinical Data on Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC at ESMO 2024.

Antennova Unveils New Data on CD73 Inhibitor ATN-037, Showcasing an 89.5% DCR, in a Brief Presentation at ESMO Congress 2024.

GV20 Therapeutics Shares Encouraging Phase 1 Monotherapy Results for New Checkpoint Inhibitor GV20-0251 at 2024 ESMO Congress.

Linnaeus Therapeutics to Present Positive Clinical Results of LNS8801 in Metastatic Melanoma at 2024 ESMO Annual Conference.

Tharimmune Secures Worldwide Rights and Collaborates With Intract Pharma to Create Oral Infliximab.

Coya Therapeutics Reports that Subcutaneously Dosed COYA 302 Shows Direct Anti-Inflammatory Effects in the Brain in a Mouse Model of Parkinson’s Disease.

Dupixent, the pioneering biologic, has shown remarkable success in reducing symptoms and achieving disease remission in a pivotal study on bullous pemphigoid.